| Synagis (palivizumab) / SOBI |
NCT00014391: Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation |
|
|
| Completed | 3 | | US | palivizumab, ribavirin | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Cancer | 10/01 | 10/01 | | |
NCT00129766: Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children |
|
|
| Completed | 3 | 6635 | Europe, Canada, US, RoW | motavizumab (MEDI-524), MEDI-524, palivizumab, Synagis | MedImmune LLC | Respiratory Syncytial Virus Infections | 05/06 | 05/06 | | |
NCT01466062 / 2014-004491-31: Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions |
|
|
| Completed | 3 | 28 | Japan | Palivizumab, ABT-315, Synagis | AbbVie (prior sponsor, Abbott) | Respiratory Syncytial Virus Infection | 04/12 | 04/12 | | |
2004-000039-27: A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children. |
|
|
| Completed | 3 | 380 | Europe, RoW | Numax, Palivizumab, MEDI-524, SYNAGIS, SYNAGIS | MedImmune, Inc., MEDIMMUNE ONCOLOGY INC | Serious respiratory syncytial virus (RSV) disease | | 05/06 | | |
NCT02968173 / 2016-000221-39: A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus |
|
|
| Completed | 3 | 50 | NA | Palivizumab, Synagis | AbbVie | Respiratory Syncytial Virus (RSV) | 07/17 | 07/17 | | |
| Completed | 3 | 420 | RoW | Palivizumab, Monoclonal antibody, Placebo, 0.9% Normal saline | Hamad Medical Corporation | Respiratory Syncytial Virus-bronchiolitis | 02/18 | 02/18 | | |
2018-002980-25: Study on prevention of respiratory consequences related to bronchiolitis caused by respiratory sincizial virus (RSV) in preterm babies Studio sulla prevenzione delle conseguenze respiratorie della bronchiolite dovuta al virus respiratorio sinciziale (VRS) nei bambini nati prematuri |
|
|
| Ongoing | 3 | 760 | Europe | palivizumab, [non disponibile], Powder and solvent for solution for injection | OSP.DEGLI INFERMI DI BIELLA, AIFA - Italian Medicines Agency | Respiratory sincizial virus (RSV) bronchiolitis bronchiolite causata dal virus respiratorio sinciziale (VRS), viral bronchiolitis bronchiolite virale, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-005996-11: Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease Evaluación controlada con palivizumab de la seguridad, la eficacia y la farmacocinética de MK-1654 en lactantes y niños con un riesgo elevado de enfermedad grave por el VRS |
|
|
| Ongoing | 3 | 1000 | Europe, RoW, Canada, Japan, US | MK-1654, Solution for injection, Synagis (Palivizumab) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Prevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV disease Prevención de la infección por virus respiratorio sincitial (VSR) en bebés y niños con mayor riesgo de enfermedad grave por VSR, Prevention of Respiratory Syncytial Virus (RSV) infection in infants. Prevención de la infección por el virus respiratorio sincitial (VSR) en niños, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 3 | 1003 | Europe, Canada, Japan, US, RoW | Clesrovimab, MK-1654, Palivizumab, Placebo | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | RSV Infection | 04/25 | 08/25 | | |
| Completed | 2/3 | 100 | RoW | palivizumab, ABT-315 (MEDI-493), Synagis 15 mg/kg intramuscularly | Abbott | Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease | 04/10 | 07/10 | | |
NCT03959488 / 2019-000201-69: A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children |
|
|
| Completed | 2/3 | 925 | Europe, Canada, Japan, US, RoW | MEDI8897, Palivizumab | AstraZeneca | Respiratory Syncytial Virus Infections | 05/21 | 01/23 | | |
